GlassScriptPhysician profile
David M Friedrich
NPI 1356720981
$7,135.81
in general payments reported to CMS, 2019-2025
19 companies · $2,026 in 2025
The $2,026 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $300 · 2021: $835 · 2022: $1,178 · 2023: $1,302 · 2024: $1,278 · 2025: $2,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,596 · Education: $10.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,596.34 |
| Education | $10.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,059.81 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,008.13 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $903.95 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $711.21 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $567.82 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $514.06 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $498.25 | 2019-2022 | |
| Alkermes, INC. | $473.13 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $425.21 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $253.31 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $228.57 | 2019-2024 | Hetlioz, Fanapt |
| Indivior INC. | $166.33 | 2022-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $165.51 | 2020-2023 | Trintellix |
| Axsome Therapeutics, INC. | $41.90 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $33.94 | 2019-2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.87 | 2023 | Abilify Asimtufii |
| Noven Therapeutics, LLC | $24.32 | 2025 | Secuado |
| Idorsia Pharmaceuticals US INC | $19.07 | 2023 | Quviviq |
| Almatica Pharma LLC | $14.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Friedrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.